The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
Official Title: Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
Study ID: NCT05645380
Brief Summary: This study will assess if the presence of immune system cells in and around the tumor impacts tumor shrinkage in patients receiving neoadjuvant chemoimmunotherapy for triple-negative breast cancer.
Detailed Description: Triple negative breast cancers (TNBC) with enrichment of immune system cells in and around the tumor are more sensitive to chemoimmunotherapy and have better prognosis. Imaging is often used during the course of neoadjuvant chemoimmunotherapy to monitor how the disease is responding to treatment, and disappearance of a patient's tumor on imaging after chemoimmunotherapy usually means that the tumor will have completely disappeared when the patient goes for surgery. This study will test whether the presence of immune system cells in and around the tumor and the response of the tumor on MRI can be used to personalize the type and amount of neoadjuvant chemoimmunotherapy for patients with TNBC.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
The University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States
The University of Kansas Cancer Center - Main Hospital, Kansas City, Kansas, United States
The University of Kansas Cancer Center - Westwood, Kansas City, Kansas, United States
The University of Kansas Cancer Center - Overland Park, Overland Park, Kansas, United States
The University of Kansas Cancer Center - North, Kansas City, Missouri, United States
The University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States
University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City, Missouri, United States
Name: Shane R Stecklein, MD, PhD
Affiliation: University of Kansas Medical Center
Role: PRINCIPAL_INVESTIGATOR